Dublin, Oct. 31, 2023 (GLOBE NEWSWIRE) -- The "Viral Vector Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ResearchAndMarkets.com's offering.
The global Viral Vector Production Market, which achieved a valuation of USD 5.22 billion in 2022, is poised for remarkable growth, with a projected Compound Annual Growth Rate (CAGR) of 14.21% through 2028. This substantial expansion is driven by the burgeoning iron & steel industry and other end-user sectors.
Viral Vector Production Fuels Medical Advancements:
Viral vector production is a transformative field dedicated to creating modified viruses, termed viral vectors, instrumental in delivering genetic material into target cells for diverse medical and biotechnological applications. These vectors serve as efficient and safe carriers for delivering therapeutic genes, rectifying genetic mutations, or manipulating cellular processes. The increased success and approval of gene therapies for various diseases, including genetic disorders and certain cancers, have elevated the demand for viral vectors as crucial delivery tools for therapeutic genes.
Key Market Drivers:
- Clinical Success of Viral Vector Production: Pioneering clinical applications have demonstrated the potential of viral vector-based therapies in addressing a range of diseases. Examples include Luxturna for inherited retinal disease and Zolgensma for spinal muscular atrophy, both showcasing the transformative capacity of viral vectors.
- Advancements in Vector Engineering: Continuous advancements enhance the efficiency, safety, and specificity of viral vectors, boosting their potential in gene therapy, gene editing, and vaccine development. Modifications improve tissue targeting, reduce immunogenicity, and enhance cellular entry for efficient gene delivery.
- Bioreactor Technology in Viral Vector Production: Bioreactors play a pivotal role in producing viral vectors, ensuring controlled environments for cell culture, transfection, and vector production. Single-use bioreactors enhance scalability, yield, quality, and regulatory compliance.
Key Challenges:
- Scalability and Commercialization: Transitioning from laboratory-scale to commercial production poses challenges, necessitating process optimization and capital-intensive manufacturing facilities adhering to regulatory standards.
- Cost of Goods and Pricing: Specialized production processes, quality control, expensive raw materials, labor costs, and regulatory compliance collectively impact affordability and accessibility.
Key Trends:
- Manufacturing Process Optimization: The focus is on refining and improving viral vector production processes to enhance efficiency, reduce costs, increase yields, and ensure consistent quality. Standardizing processes ensures uniformity, regulatory compliance, and quality.
- Segmental Insights: AAV vectors dominate the market, downstream processing plays a crucial role, gene therapy applications thrive, and research institutes lead in adopting advanced therapies.
- Regional Dominance: North America leads the market, propelled by government support, financing, and a thriving R&D environment for advanced therapeutics.
Key Market Players
- Merck kgaa
- Lonza
- FUJIFILM Diosynth Biotechnologies U.S.A
- Cobra Biologics Ltd.
- Thermofisher Scientific Inc.
- Waisman Biomanufacturing
- Genezen Laboratories
- YPOSKESI
- Advanced BioScience Laboratories, Inc. (ABL inc.)
- Novasep Holding s.a.s.
- Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
- Takara Bio Inc.
- RegenxBio, Inc.
- Aldevron LLc.
- Bluebird Bio Inc.
Report Scope:
In this report, the Global Viral Vector Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Viral Vector Production Market, By Vector Type:
- Adenovirus
- AAV
- Lentivirus
- Retrovirus
- Others
Viral Vector Production Market, By Workflow:
- Upstream Processing
- Vector amplification and expansion
- Vector recovery/harvesting
- Downstream Processing
- Purification
- Fill finish
Viral Vector Production Market, By Application:
- Gene and Cell Therapy Development
- Vaccine Development
- Biopharmaceutical and Pharmaceutical Discovery
- Biomedical Research
Viral Vector Production Market, By End User:
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
Global Viral Vector Production Market, By region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 178 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $5.22 Billion |
| Forecasted Market Value (USD) by 2028 | $11.54 Billion |
| Compound Annual Growth Rate | 14.2% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/empx4l
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
